the baseline score of the corresponding PRO dimension. The mean change in the GSRS reflux dimension for patients with severe reflux symptoms at baseline (n = 361) was 3.46; the mean change in the QOLRAD sleep dimension in patients with severe sleep disturbances (n = 308) was 3.34; and the mean change in the QOLRAD eat/drink dimension in patients with severe eat/drink problems (n = 399) was 3.26. The corresponding changes in patients with none/minor symptoms or problems at baseline were 0.67, 0.45, and 0.56 for reflux (n = 3161, sleep disturbances (n = 638), and eat/drink problems (n = 2981, respectively In patients with moderate symptoms or problems at baseline, the change scores were 2.54, 2.40, and 2.32 for reflux (n = 541), sleep (n = 389), and eat/drink (n = 570) dimensions, respectively However, regardless of baseline severity of symptoms or problems, -80% of the patients considered their symptoms to be at least “moderately better” according to the OTE. DISCUSSION: The baseline PRO score has a profound influence on the magnitude of score change during treatment but not on the clinical relevance of the change as measured by the OTE. This must be taken into account when interpreting the magnitude of score changes in terms of clinical relevance.